Zoetis reports conditional license from USDA for Avian Influenza Vaccine

Zoetis (ZTS) announced that the U.S. Department of Agriculture, Center for Veterinary Biologics, has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. “The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data,” the company stated. “When a new strain of HPAI was identified in the U.S. in early 2022, our scientists immediately began work to update our previous avian influenza vaccine,” said Mahesh Kumar, Ph.D., senior vice president, global biologics research and development at Zoetis. “We first worked on HPAI vaccines in 2001-02 when outbreaks occurred in flocks in Southeast Asia. Our readiness with this most recent vaccine is another example of how we continue to live our purpose to nurture the world and humankind by advancing care for animals, ultimately providing solutions to global animal health challenges.”